Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHRISTOPHER J LUCASTI

Allopathic & Osteopathic Physicians Internal Medicine Infectious Disease

NPI
1467447417
CMS profile
201803
Location
SOMERS POINT, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$9,988.15

137 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 137 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHRISTOPHER J LUCASTI

NPI 1467447417 · CMS profile ID 201803

Allopathic & Osteopathic Physicians / Internal Medicine / Infectious Disease

SOMERS POINT, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 137 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1467447417?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHRISTOPHER J LUCASTI, NPI 1467447417, CMS profile ID 201803. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 137 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1467447417?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). CHRISTOPHER J LUCASTI, NPI 1467447417, CMS profile ID 201803. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 137 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1467447417?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
CHRISTOPHER J LUCASTI, NPI 1467447417, CMS profile ID 201803, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 137 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1467447417?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

137 matching records · $9,988.15 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 137 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 137.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Insmed, Inc. $31.4907/27/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 906436089 CMS
Insmed, Inc. $19.0907/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 906453557 CMS
ViiV Healthcare Company $7.9307/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944116241 CMS
ViiV Healthcare Company $13.4107/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944116195 CMS
Merck Sharp & Dohme LLC $13.9307/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944436365 CMS
ViiV Healthcare Company $13.9307/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944116097 CMS
Gilead Sciences, Inc. $14.4207/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929514325 CMS
Gilead Sciences, Inc. $6.2707/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929514285 CMS
ViiV Healthcare Company $16.8007/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944116139 CMS
ABBVIE INC. $12.9607/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891058787 CMS
Janssen Biotech, Inc. $16.8507/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886197817 CMS
ViiV Healthcare Company $14.4806/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944116277 CMS
Merck Sharp & Dohme LLC $13.9206/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944437079 CMS
ViiV Healthcare Company $14.0206/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944116089 CMS
EMD Serono, Inc. $14.3806/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941529422 CMS
Smith+Nephew, Inc. $14.7206/20/2022 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 960839917 CMS
Melinta Therapeutics, LLC $14.8206/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 960317377 CMS
ViiV Healthcare Company $1.4706/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944116081 CMS
Gilead Sciences, Inc. $13.0106/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929514303 CMS
Gilead Sciences, Inc. $24.0006/09/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929463377 CMS
Gilead Sciences, Inc. $81.2106/09/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929463383 CMS
Gilead Sciences, Inc. $247.4406/09/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929463389 CMS
Gilead Sciences, Inc. $587.2006/09/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929463395 CMS
ViiV Healthcare Company $14.9906/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944116283 CMS
Cumberland Pharmaceuticals, Inc. $86.0306/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951783537 CMS
Gilead Sciences, Inc. $8.2106/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929514289 CMS
Gilead Sciences, Inc. $1.7705/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929514273 CMS
ViiV Healthcare Company $13.0805/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944116245 CMS
Insmed, Inc. $15.3205/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 906415829 CMS
ViiV Healthcare Company $4.4305/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944116337 CMS
ViiV Healthcare Company $14.1205/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944116355 CMS
Gilead Sciences, Inc. $8.7605/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929514293 CMS
Merck Sharp & Dohme LLC $14.8005/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944439073 CMS
Janssen Biotech, Inc. $13.6505/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886197806 CMS
Gilead Sciences, Inc. $1.8005/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929514275 CMS
Napo Pharmaceuticals Inc $14.0305/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951969519 CMS
ViiV Healthcare Company $4.0005/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944116321 CMS
Gilead Sciences, Inc. $8.5305/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929514291 CMS
EMD Serono, Inc. $12.3105/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941511857 CMS
ABBVIE INC. $14.5105/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891058785 CMS
ViiV Healthcare Company $17.2104/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944116199 CMS
Gilead Sciences, Inc. $13.4104/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929514309 CMS
Gilead Sciences, Inc. $3,760.0004/14/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929446633 CMS
Gilead Sciences, Inc. $27.1704/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929514329 CMS
Gilead Sciences, Inc. $42.5604/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929514331 CMS
Gilead Sciences, Inc. $44.5204/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929514333 CMS
Merck Sharp & Dohme LLC $12.8504/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944463377 CMS
ViiV Healthcare Company $13.0604/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944116113 CMS
Cumberland Pharmaceuticals, Inc. $90.4003/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951783533 CMS
Gilead Sciences, Inc. $5.1703/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929514281 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $23,353.64 150
PY2020 $9,796.45 118
PY2021 $14,996.50 158
PY2022 $9,988.15 137
PY2023 $21,475.09 144
PY2024 $15,824.36 133
PY2025 $16,382.08 175

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $84,781.78 38
PY2024 Principal investigator $148,606.18 36
PY2023 Recipient $1,311.01 8
PY2023 Principal investigator $286,334.21 72
PY2022 Principal investigator $681,829.64 102
PY2021 Principal investigator $643,732.79 89
PY2020 Principal investigator $597,023.90 40
PY2019 Principal investigator $248,371.32 48

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

38 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $11,000.00 11/26/2025 Non-covered Recipient Entity
South Jersey Infectious Disease
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228739146
Principal investigator 1 PFIZER INC. $1,586.00 11/25/2025 Non-covered Recipient Entity
South Jersey Infectious Disease
A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228728053
Principal investigator 1 PFIZER INC. $426.60 11/21/2025 Non-covered Recipient Entity
South Jersey Infectious Disease
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228725644
Principal investigator 1 PFIZER INC. $426.60 11/21/2025 Non-covered Recipient Entity
South Jersey Infectious Disease
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228725646
Principal investigator 1 PFIZER INC. $426.60 11/21/2025 Non-covered Recipient Entity
South Jersey Infectious Disease
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228725648
Principal investigator 1 PFIZER INC. $426.60 11/21/2025 Non-covered Recipient Entity
South Jersey Infectious Disease
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228726272
Principal investigator 1 PFIZER INC. $426.60 11/21/2025 Non-covered Recipient Entity
South Jersey Infectious Disease
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228732537
Principal investigator 1 PFIZER INC. $426.60 11/21/2025 Non-covered Recipient Entity
South Jersey Infectious Disease
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228733282
Principal investigator 1 PFIZER INC. $426.60 11/21/2025 Non-covered Recipient Entity
South Jersey Infectious Disease
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228735218
Principal investigator 1 PFIZER INC. $426.60 11/21/2025 Non-covered Recipient Entity
South Jersey Infectious Disease
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228735834
Principal investigator 1 PFIZER INC. $426.60 11/21/2025 Non-covered Recipient Entity
South Jersey Infectious Disease
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228735994
Principal investigator 1 PFIZER INC. $426.60 11/21/2025 Non-covered Recipient Entity
South Jersey Infectious Disease
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228736050
Principal investigator 1 Gilead Sciences, Inc. $1,255.00 11/18/2025 Non-covered Recipient Entity
SOUTH JERSEY INFECTIOUS DISEASE
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229220363
Principal investigator 1 PFIZER INC. $180.80 11/11/2025 Non-covered Recipient Entity
South Jersey Infectious Disease
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228724792
Principal investigator 1 PFIZER INC. $265.20 11/11/2025 Non-covered Recipient Entity
South Jersey Infectious Disease
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228724998
Principal investigator 1 ABBVIE INC. $3,365.00 11/04/2025 Non-covered Recipient Entity
SOUTH JERSEY INFECTIOUS DISEASE
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202520717
Principal investigator 1 Gilead Sciences, Inc. $1,559.00 10/21/2025 Non-covered Recipient Entity
SOUTH JERSEY INFECTIOUS DISEASE
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229220353
Principal investigator 1 Gilead Sciences, Inc. $1,559.00 09/16/2025 Non-covered Recipient Entity
SOUTH JERSEY INFECTIOUS DISEASE
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229220338
Principal investigator 1 Gilead Sciences, Inc. $2,763.00 08/19/2025 Non-covered Recipient Entity
SOUTH JERSEY INFECTIOUS DISEASE
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229220330
Principal investigator 1 Merck Sharp & Dohme LLC $4,408.00 08/06/2025 Non-covered Recipient Entity
SOUTH JERSEY INFECTIOUS DISEASE
A Test-Negative Case-Control Study to Evaluate the Effectiveness of V116 Against Pneumococcal Pneumonia in Older Adults No dispute reported 06/30/2026 1232940133
Principal investigator 1 PFIZER INC. $1,373.04 07/25/2025 Non-covered Recipient Entity
South Jersey Infectious Disease
A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228763521
Principal investigator 1 ABBVIE INC. $510.30 07/02/2025 Non-covered Recipient Entity
SOUTH JERSEY INFECTIOUS DISEASE
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202494871
Principal investigator 1 Gilead Sciences, Inc. $2,396.00 06/17/2025 Non-covered Recipient Entity
SOUTH JERSEY INFECTIOUS DISEASE
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229220317
Principal investigator 1 ABBVIE INC. $610.60 06/12/2025 Non-covered Recipient Entity
SOUTH JERSEY INFECTIOUS DISEASE
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202491337
Principal investigator 1 ABBVIE INC. $1,845.90 06/03/2025 Non-covered Recipient Entity
SOUTH JERSEY INFECTIOUS DISEASE
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202489499
Principal investigator 1 PFIZER INC. $457.68 05/23/2025 Non-covered Recipient Entity
South Jersey Infectious Disease
A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228767335
Principal investigator 1 Gilead Sciences, Inc. $2,453.00 05/20/2025 Non-covered Recipient Entity
SOUTH JERSEY INFECTIOUS DISEASE
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229220309
Principal investigator 1 ABBVIE INC. $1,530.90 05/07/2025 Non-covered Recipient Entity
SOUTH JERSEY INFECTIOUS DISEASE
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202483273
Principal investigator 1 PFIZER INC. $915.36 04/24/2025 Non-covered Recipient Entity
South Jersey Infectious Disease
A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228798187
Principal investigator 1 Gilead Sciences, Inc. $1,559.00 04/22/2025 Non-covered Recipient Entity
SOUTH JERSEY INFECTIOUS DISEASE
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229220299
Principal investigator 1 Merck Sharp & Dohme LLC $19,440.00 04/14/2025 Non-covered Recipient Entity
SOUTH JERSEY INFECTIOUS DISEASE
A Test-Negative Case-Control Study to Evaluate the Effectiveness of V116 Against Pneumococcal Pneumonia in Older Adults No dispute reported 06/30/2026 1232940149
Principal investigator 1 ABBVIE INC. $1,020.60 04/03/2025 Non-covered Recipient Entity
SOUTH JERSEY INFECTIOUS DISEASE
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202469674
Principal investigator 1 Gilead Sciences, Inc. $1,559.00 03/18/2025 Non-covered Recipient Entity
SOUTH JERSEY INFECTIOUS DISEASE
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229220287
Principal investigator 1 ABBVIE INC. $3,181.50 03/07/2025 Non-covered Recipient Entity
SOUTH JERSEY INFECTIOUS DISEASE
M19-965 - A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202459313
Principal investigator 1 Gilead Sciences, Inc. $4,705.00 02/19/2025 Non-covered Recipient Entity
SOUTH JERSEY INFECTIOUS DISEASE
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229220274
Principal investigator 1 ABBVIE INC. $3,144.00 02/06/2025 Non-covered Recipient Entity
SOUTH JERSEY INFECTIOUS DISEASE
M19-965 - A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202449739
Principal investigator 1 Gilead Sciences, Inc. $4,342.00 01/22/2025 Non-covered Recipient Entity
SOUTH JERSEY INFECTIOUS DISEASE
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229220264
Principal investigator 1 ABBVIE INC. $1,530.90 01/02/2025 Non-covered Recipient Entity
SOUTH JERSEY INFECTIOUS DISEASE
M19-965 - A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202434873